ONXX Related Analyst Ratings
-
Craig-Hallum Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Buy
-
Canaccord Adams Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); Lowers PT & Estimates
-
Onyx Pharmaceuticals (ONXX) Higher On Proteolix Acquisition, But Not Everyone Convinced
-
Cowen Downgrades Onyx Pharma (ONXX) to Market Perform
-
Canaccord Adams Calls Onyx Phama (ONXX) A Top 2nd-Half Pick
-
BMO Capital Downgrades Onyx Pharmaceuticals (ONXX) to Market Perform
-
Morgan Joseph Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); Sees Nexavar Sales at $2 Billion By 2015
-
Caris Downgrades Onyx Pharma (ONXX) to Above Average
-
BMO Capital Upgrades Onyx Pharmaceuticals (ONXX) to Outperform
-
Baird Starts Onyx Pharmaceuticals (ONXX) at Outperform
-
Boenning & Scattergood Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Neutral
-
Morgan Joseph Starts Onyx Pharmaceuticals (ONXX) at Buy
-
Barclays Gets Bullish On US Biotechnology Sector (BBH)
-
Canaccord Adams Maintains a 'Buy' on Onyx Pharmaceuticals (ONXX); Concerns Baked In
-
Canaccord Adams Initiates Coverage on Several Life Sciences Stocks: ALTH, EXEL, MITI, NPSP, OSIP, ONXX, PARD, SGEN & SNTA
-
JP Morgan Upgrades Onyx Pharmaceuticals (ONXX) to Overweight
-
Janney Montgomery Scott Upgrades Onyx Pharmaceuticals (ONXX) to Buy
-
Morgan Stanley Downgrades Onyx Pharmaceuticals (ONXX) to Underweight
-
Susquehanna Initiates Coverage on Onyx Pharmaceuticals (ONXX)
-
Caris Starts Onyx Pharma (ONXX) at Above Average
-
Merrill Lynch Downgrades Onyx Pharmaceuticals (ONXX) to Underperform
-
Barron's Article Makes Positive Comments on Onyx Pharmaceuticals (ONXX)
-
Onyx Pharma (NASDAQ:ONXX): Strong bounce candidate below $40
-
Goldman Sachs Starts Onyx Pharmaceuticals (ONXX) at Neutral
-
Who's The Next Biotech Target Following Celgene/Pharmion?
-
Bear Stearns downgrades Onyx Pharmaceuticals (ONXX) to Peer Perform
-
Bear Stearns Upgrades Onyx Pharma (ONXX) to Outperform
-
Friedman Billings upgrades Onyx Pharma (ONXX) to Market Perform
-
Janney Montgomery Downgrades Onyx Pharmaceuticals (ONXX) to Neutral
-
Friedman Billings downgrades Onyx Pharma (ONXX) to Underperform
-
Friedman Billings Upgrades Onyx Pharmaceuticals (ONXX) to Market Perform
-
Citigroup Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Hold
-
Miller Johnson Starts Onyx Pharmaceuticals (ONXX) at Market Perform
-
Friedman Billings downgrades Onyx Pharma (ONXX) to Underperform
-
Banc of America upgrades Onyx Pharma (ONXX) to Buy
-
Janney upgrades Onyx Pharma (ONXX) to Buy
-
Wachovia upgrades Onyx Pharma (ONXX) to Outperform
-
Prudential upgrades Onyx Pharma (ONXX) to Overweight
-
Piper Jaffray Said BAY/ONXX Approval for Nexavar is a Positive for EXEL
-
Piper Jaffray Comments on ONXX; Sees Busy Quarter for Kidney Cancer Drugs
-
WR Hambrecht Starts ONXX at Hold
-
Leerink Swann Downgraded ONXX
-
Bear Stearns Downgraded ONXX
-
JP Morgan Downgrades ONXX; PFE competition fears
-
Banc of America Initiates Coverage on a Number of Biotech Stocks
-
Wachovia upgrades ONXX to Market Perform
-
Merrill Lynch Resumed Coverage on ONXX
-
ONXX Coverage
-
Wachovia Securities Downgrades ONXX
-
Friedman Billings Downgrades ONXX
Back to ONXX Stock Lookup
